Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 1997Journal of Biological ChemistryOpen Access

BH3 Domain of BAD Is Required for Heterodimerization with BCL-XL and Pro-apoptotic Activity

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJiping ZhaTeradata (United States)HHHisashi HaradaVirginia Commonwealth UniversityKOKonstantin A OsipovInstitute of Cytology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zha et al. (1997) studied this question.

synapsesocial.com/papers/6a710866e5469ee92be1ab3dhttps://doi.org/10.1074/jbc.272.39.24101
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Induction of Apoptosis by Human Nbk/Bik, a BH3-Containing Protein That Interacts with E1B 19K1996 · 199 citations
  2. 2Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH21996 · 462 citations
  3. 3BID: a novel BH3 domain-only death agonist.1996 · 976 citations